封面
市场调查报告书
商品编码
1629585

生物製药和生物医学市场:按产品类型、按应用、按类型、按给药途径、按患者人口统计、按地区

Biopharmaceutical and Biomedicine Market, By Product Type (Biopharmaceuticals, By Application (Therapeutics, and Diagnostics, By Type, By Route of Administration, By Patient Demographics, By Geography

出版日期: | 出版商: Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计2024年全球生物製药和生物医学市场规模为5,711亿美元,预计2031年将达到1,2,542.1亿美元,2024年至2031年复合年增长率为11.9%。

报告范围 报告详情
基准年 2023年 2024年市场规模 5711亿美元
实际资料 2019-2023 预测期 2024-2031
预测 2024-2031 年复合年增长率: 11.90% 2031年价值预测 1,254,210 百万美元
图:2024 年按地区分類的生物製药和生物医药的全球市场占有率(%)
生物製药及生物医学市场-IMG1

全球生物製药和生物医学市场在过去几十年中经历了显着成长。公共和私营部门对研发活动的投资增加正在导致生技药品、基因工程和开发新药领域的突破性创新。细胞和基因治疗、再生医学、单株抗体和个人化医疗领域的进步为慢性和危及生命的疾病的治疗提供了广阔的前景。人口迅速老化以及全球癌症、糖尿病和神经系统疾病盛行率的上升正在推动对更有效治疗方案的需求。此外,合成生物学和基因工程的重大进步使科学家能够设计和开发先进的生技药品,例如疫苗、荷尔蒙和血液成分,这些产品在医疗保健和其他工业领域具有重要的应用。儘管成长机会依然巨大,但高昂的研发成本和严格的法规仍然是挑战。

市场动态:

推动全球生物製药和生物医学市场成长的主要因素是慢性病和文明病的盛行率上升、容易受到各种健康问题影响的老龄化人口的迅速增加以及优质医疗保健产品的可用性。的服务需求。此外,公共和私人对先进蛋白质工程、重组 DNA 技术和干细胞研究的大量投资正在促进新型生物药品和治疗方法的开发。然而,药物开发从临床试验到核准的极高成本,加上精细的製造流程和严格的法律规范,继续限制市场的快速扩张。同时,对个人化医疗和组织器官3D生物列印的日益关注为市场发展提供了新的途径。此外,研究机构和产业参与者之间的伙伴关係有助于加速有前景的候选药物的商业化并降低生产成本。

本研究的主要特点

本报告对全球生物製药和生物医药市场进行了详细分析,并列出了以2023年为基准年的预测期(2024-2031年)的市场规模和年复合成长率(CAGR%)。

它还揭示了各个细分市场的潜在商机,并说明了该市场有吸引力的投资提案矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。

根据公司亮点、产品系列、主要亮点、财务表现和策略等参数对全球生物製药和生物医药市场的主要企业进行了分析。

主要企业包括诺华公司、强生公司、辉瑞公司、赛诺菲公司、礼来公司、罗氏公司、艾伯维公司、百时美施贵宝、Qiagen NV、Affimed NV、新基公司、安进公司。克公司、葛兰素史克公司和再生元製药公司。

该报告的见解将帮助负责人和公司经营团队就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。

本研究报告针对该产业的各个相关人员,如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。

透过用于分析全球生物製药和生物医学市场的各种策略矩阵,将有助于相关人员做出决策。

目录

第一章 研究目的与前提

  • 研究目的
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要

第三章市场动态、法规及趋势分析

  • 市场动态
  • 促进因素
  • 抑制因素
  • 机会
  • 影响分析
  • 主要进展
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特分析
  • 併购场景
  • 产业动态

第四章全球生物製药和生物医学市场,依产品类型,2019-2031

  • 生物製药
  • 奈米医学
  • 细胞/基因治疗
  • 生物资讯学
  • 分子酵素和套件

第五章全球生物製药和生物医学市场,依应用分类,2019-2031

  • 治疗
  • 诊断
  • 研究与开发

第六章2019-2031年全球生物製药和生物医学市场(按类型)

  • 品牌生物製药
  • 非专利药生物製药

第七章 全球生物製药和生物医学市场,依管理途径,2019-2031

  • 口服
  • 静脉
  • 皮下的
  • 肌肉注射

第 8 章 全球生物製药和生物医学市场,按患者人口统计数据,2019-2031

  • 成人
  • 儿科的
  • 老年人

第九章2019-2031年全球生物製药和生物医药市场(按地区)

  • 北美洲
  • 拉丁美洲
  • 欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
    • ASEAN
    • 其他亚太地区
  • 中东
    • 海湾合作委员会国家
    • 以色列
    • 其他中东地区
  • 非洲
    • 南非
    • 北非
    • 中部非洲

第10章竞争格局

  • Novartis AG
  • Johnson & Johnson
  • Pfizer, Inc.
  • Sanofi SA
  • Eli Lilly and Company
  • F.Hoffmann-La Roche AG
  • AbbVie Inc.
  • Bristol-Myers Squibb
  • Qiagen NV
  • Affimed NV
  • Celgene Corporation
  • Amgen Inc.
  • Merck & Co., Inc.
  • GSK Plc
  • Regeneron Pharmaceuticals

第十一章分析师建议

  • 命运之轮
  • 分析师观点
  • 一致的机会图

第十二章参考文献与调查方法

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI18

The Global Biopharmaceutical and Biomedicine Market is estimated to be valued at USD 571.10 Bn in 2024 and is expected to reach USD 1,254.21 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 11.9% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 571.10 Bn
Historical Data for: 2019 To 2023 Forecast Period: 2024 To 2031
Forecast Period 2024 to 2031 CAGR: 11.90% 2031 Value Projection: US$ 1,254.21 Bn
Figure. Global Biopharmaceutical and Biomedicine Market Share (%), By Region 2024
Biopharmaceutical and Biomedicine Market - IMG1

The global biopharmaceutical and biomedicine market has witnessed tremendous growth over the past few decades. Rising investment in research and development activities by both public and private sectors has led to path breaking innovations in the field of biologics, genetic engineering and novel drug development. Advancements in areas such as cell and gene therapy, regenerative medicine, monoclonal antibodies and personalized medicine holds promising prospects for the treatment of chronic and life-threatening diseases. Rapidly aging population and growing incidence of cancer, diabetes and neurological disorders globally has spurred demand for more effective therapeutic options. Moreover, substantial progress in synthetic biology and genetic engineering is allowing scientists to design and develop advanced biologics like vaccines, hormones and blood components, with significant applications in healthcare and other industrial verticals. While growth opportunities remain vast, high R&D costs and stringent regulatory framework continue posing challenges.

Market Dynamics:

The key factors driving the growth of global biopharmaceutical and biomedicine market include rising prevalence of chronic and lifestyle diseases, rapid increase in geriatric population susceptible to various health issues, growing demand for superior healthcare products and services. Moreover, heavy investments by both public and private players in advanced protein engineering, recombinant DNA technology and stem cell research have enabled development of novel biologic drugs and therapies. However, extremely high costs associated with drug development from clinical trial to approval, coupled with delicate manufacturing processes and stringent regulatory oversight continue to restrain faster market expansion. At the same time, growing focus on personalized medicine and 3D bioprinting of tissues and organ present new avenues for market progress. In addition, partnerships between research institutes and industry players are helping accelerate commercialization of promising drug candidates and lower production costs.

Key Features of the Study:

This report provides in-depth analysis of the global biopharmaceutical and biomedicine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global biopharmaceutical and biomedicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb, Qiagen N.V., Affimed N.V., Celgene Corporation, Amgen Inc., Merck & Co., Inc., GSK Plc, and Regeneron Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global biopharmaceutical and biomedicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biopharmaceutical and biomedicine market

Market Segmentation

  • Product Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Biopharmaceuticals
    • Monoclonal Antibodies
    • Vaccines
    • Recombinant Human Insulin
    • Human Growth Hormone
    • Erythropoietin
    • Interferon
    • Colony Stimulating Factor
    • Blood Factors
    • Fusion Protein
    • Others
    • Nanomedicine
    • Cell & Gene Therapy
    • Bioinformatics
    • Molecular Enzymes & Kits
  • Application Insights (Revenue, USD Bn, 2019 - 2031)
    • Therapeutics
    • Oncology
    • Cardiovascular Diseases
    • Neurological Disorders
    • Infectious Diseases
    • Immune Disorders
    • Diagnostics
    • In Vitro Diagnostics
    • In Vivo Diagnostics
    • Point-of-Care Testing
    • Research and Development
    • Preclinical Research
    • Clinical Trials
    • Biotechnology Research
    • Regulatory Research
  • Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Branded Biopharmaceuticals
    • Generic Biopharmaceuticals
  • Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
    • Oral
    • Intravenous
    • Subcutaneous
    • Intramuscular
  • Patient Demographics Insights (Revenue, USD Bn, 2019 - 2031)
    • Adult
    • Pediatric
    • Geriatric
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Novartis AG
    • Johnson & Johnson
    • Pfizer, Inc.
    • Sanofi S.A.
    • Eli Lilly and Company
    • F.Hoffmann-La Roche AG
    • AbbVie Inc.
    • Bristol-Myers Squibb
    • Qiagen N.V.
    • Affimed N.V.
    • Celgene Corporation
    • Amgen Inc.
    • Merck & Co., Inc.
    • GSK Plc
    • Regeneron Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Biopharmaceutical and Biomedicine Market, By Product Type
    • Global Biopharmaceutical and Biomedicine Market, By Application
    • Global Biopharmaceutical and Biomedicine Market, By Type
    • Global Biopharmaceutical and Biomedicine Market, By Route of Administration
    • Global Biopharmaceutical and Biomedicine Market, By Patient Demographics
    • Global Biopharmaceutical and Biomedicine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Biopharmaceutical and Biomedicine Market, By Product Type, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Biopharmaceuticals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    • Monoclonal Antibodies
    • Vaccines
    • Recombinant Human Insulin
    • Human Growth Hormone
    • Erythropoietin
    • Interferon
    • Colony Stimulating Factor
    • Blood Factors
    • Fusion Protein
    • Others
  • Nanomedicine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Cell & Gene Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Bioinformatics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Molecular Enzymes & Kits
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Biopharmaceutical and Biomedicine Market, By Application, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Therapeutics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    • Oncology
    • Cardiovascular Diseases
    • Neurological Disorders
    • Infectious Diseases
    • Immune Disorders
  • Diagnostics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    • In Vitro Diagnostics
    • In Vivo Diagnostics
    • Point-of-Care Testing
  • Research and Development
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    • Preclinical Research
    • Clinical Trials
    • Biotechnology Research
    • Regulatory Research

6. Global Biopharmaceutical and Biomedicine Market, By Type, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Branded Biopharmaceuticals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Generic Biopharmaceuticals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Biopharmaceutical and Biomedicine Market, By Route of Administration, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Subcutaneous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Intramuscular
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Biopharmaceutical and Biomedicine Market, By Patient Demographics, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Biopharmaceutical and Biomedicine Market, By Region, 2019 - 2031, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Patient Demographics, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Patient Demographics, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
      • South Africa
      • North Africa
      • Central Africa

10. Competitive Landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
  • Pfizer, Inc.
  • Sanofi S.A.
  • Eli Lilly and Company
  • F.Hoffmann-La Roche AG
  • AbbVie Inc.
  • Bristol-Myers Squibb
  • Qiagen N.V.
  • Affimed N.V.
  • Celgene Corporation
  • Amgen Inc.
  • Merck & Co., Inc.
  • GSK Plc
  • Regeneron Pharmaceuticals

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us